Morphine withdrawal enhances hepatitis C virus replicon expression.
We previously demonstrated that morphine enhances hepatitis C virus (HCV) replication in human hepatic cells. Here we describe the impact of morphine withdrawal (MW), a recurrent event during the course of opioid abuse, on HCV replicon expression in human hepatic cells. MW enhanced both viral RNA and protein expression in HCV replicon cells. Blocking opioid receptors by treatment with naloxone after morphine cessation (precipitated withdrawal, PW) induced greater HCV replicon expression than MW. Investigation of the mechanism responsible for MW- or PW-mediated HCV enhancement showed that both MW and PW inhibited the expression of endogenous interferon-alpha (IFN-alpha) in the hepatic cells. This down-regulation of intracellular IFN-alpha expression was due to the negative impact of MW or PW on IFN-alpha promoter activation and on the expression of IFN regulatory factor 7 (IRF-7), a strong transactivator of the IFN-alpha promoter. In addition, both MW and PW inhibited the anti-HCV ability of recombinant IFN-alpha in the hepatic cells. These in vitro observations support the concept that opioid abuse favors HCV persistence in hepatic cells by suppressing IFN-alpha-mediated intracellular innate immunity and contributes to the development of chronic HCV infection.
Wang
Chuan-Qing
CQ
Department of Pediatrics, Division of Allergy and Immunology, The Children's Hospital of Philadelphia, and the Department of Psychiatry, University of Pennsylvania School of Medicine, 34th St. and Civic Center Blvd., Philadelphia, PA 19104, USA.
Li
Yuan
Y
Douglas
Steven D
SD
Wang
Xu
X
Metzger
David S
DS
Zhang
Ting
T
Ho
Wen-Zhe
WZ
D002460:Cell Line; D015536:Down-Regulation; D015870:Gene Expression / Q000187:drug effects; D016174:Hepacivirus / Q000235:genetics*; D006526:Hepatitis C / Q000821:virology*; D022781:Hepatocytes / Q000821:virology*; D006801:Humans; D050839:Interferon Regulatory Factor-7 / Q000096:biosynthesis / Q000235:genetics; D007370:Interferon Type I / Q000494:pharmacology; D016898:Interferon-alpha / Q000096:biosynthesis / Q000235:genetics; D009020:Morphine / Q000009:adverse effects* / Q000494:pharmacology; D009021:Morphine Dependence / Q000150:complications*; D009270:Naloxone / Q000494:pharmacology; D009292:Narcotic Antagonists / Q000494:pharmacology; D011401:Promoter Regions, Genetic; D012333:RNA, Messenger / Q000032:analysis; D012367:RNA, Viral / Q000096:biosynthesis; D011994:Recombinant Proteins; D012093:Replicon; D013375:Substance Withdrawal Syndrome; D014764:Viral Proteins / Q000096:biosynthesis; D014779:Virus Replication
D050839:Interferon Regulatory Factor-7; D007370:Interferon Type I; D016898:Interferon-alpha; D009292:Narcotic Antagonists; D012333:RNA, Messenger; D012367:RNA, Viral; D011994:Recombinant Proteins; D014764:Viral Proteins; D009270:Naloxone; D009020:Morphine